A Study of TAK-881 and HyQvia in Healthy Adults
1期
已完成
NCT06895967
| 适应症 | Healthy Volunteers |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Takeda |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 30 人 |
|---|
| 干预（药物） | TAK-881, HyQvia, SC Investigational Needle Sets, SC Investigational Needle Sets |
|---|
| 开始日期 | 2025年3月24日 |
|---|
| 完成日期 | 2025年7月24日 |
|---|
| 结果公布日 | 2026年5月11日 |
|---|
摘要
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels
Day 1 up to Day 29 · gram*hour per liter (g*h/L)
| TAK-881 1.0 g/kg | 2993 ± 13.6 gram*hour per liter (g*h/L) |
|---|
| HyQvia 1.0 g/kg | 3190 ± 25.4 gram*hour per liter (g*h/L) |
|---|
| Geometric mean ratio | 93.82 (95% CI 80.38–109.52) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。